Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Technology appraisal guidance
Reference number: TA563
Published: 27 February 2019

History

Documents created during the development process.

Declaration of interests

Register of interests (PDF 147 KB)

Published:

17 February 2020

Expected publication

Equality Impact Assessment (Guidance development) (PDF 159 KB)

Published:

27 February 2019

Final draft guidance

Final draft guidance
Final appraisal document (PDF 348 KB)

Published:

17 January 2019
Committee papers (PDF 947 KB)

Published:

17 January 2019
Public committee slides (PDF 525 KB)

Published:

17 January 2019

Draft guidance

Draft guidance
Appraisal consultation document (PDF 374 KB)

Published:

19 October 2018
Committee papers (PDF 21.33 MB)

Published:

19 October 2018
Public committee slides (PDF 1.1 MB)

Published:

19 October 2018

Invitation to participate

Final scope (PDF 228 KB)

Published:

16 April 2018
Final matrix (PDF 339 KB)

Published:

16 April 2018
NICE's response to comments on the draft scope and provisional matrix (PDF 239 KB)

Published:

18 April 2018

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft scope post referral (PDF 335 KB)

Published:

26 October 2017
Draft matrix post referral (PDF 342 KB)

Published:

26 October 2017